Literature DB >> 18334748

Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.

Dipa Patel1, Paul Balderes, Armin Lahiji, Maxine Melchior, Stanley Ng, Rajiv Bassi, Yan Wu, Heather Griffith, Xenia Jimenez, Dale L Ludwig, Daniel J Hicklin, Xiaoqiang Kang.   

Abstract

TYRP1 (tyrosinase-related protein 1) is a melanoma antigen expressed in melanosomes and on the surface of melanoma cells. Previous studies have shown that mouse antibodies to TYRP1 localized to melanomas in vivo and inhibited tumor growth and metastasis. Here, we describe the characterization of a novel fully human anti-TYRP1 MAb (20D7) generated by immunizing HuMAb mice (Medarex). 20D7 recognized recombinant and native human TYRP1 by Western blotting and ELISA, and native TYRP1 in melanoma cells as determined by flow cytometry analysis. 20D7 cross-reacted with mouse TYRP1. The binding affinity to human TYRP1 for the human MAb was in the low nM range as determined by surface plasmon resonance kinetics. 20D7 can bind to human and mouse Fc receptor and induce a strong ADCC response against human melanoma cells in vitro. The antitumor activity of 20D7 was tested in human melanoma xenografts and mouse metastatic melanoma models in athymic nude mice. Growth of s.c. human melanoma tumors and metastatic nodules of murine B16 tumor were significantly suppressed by 20D7 compared to human IgG control. These results suggest that human anti-TYRP1 MAb may be a potent therapeutic for the treatment of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18334748

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  9 in total

1.  Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Authors:  Yvonne M Saenger; Yanyun Li; Karoline C Chiou; Brian Chan; Gabrielle Rizzuto; Stephanie L Terzulli; Taha Merghoub; Alan N Houghton; Jedd D Wolchok
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

2.  Melanoma--the pieces of the puzzle finally start coming together! Preface.

Authors:  Alan Spatz; Alexander M M Eggermont
Journal:  Mol Oncol       Date:  2011-04-03       Impact factor: 6.603

3.  Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.

Authors:  Alice Tzeng; Byron H Kwan; Cary F Opel; Tejas Navaratna; K Dane Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

Review 4.  Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma.

Authors:  Ghanem Ghanem; Journé Fabrice
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

Review 5.  New perspectives on the role of vitiligo in immune responses to melanoma.

Authors:  Katelyn T Byrne; Mary Jo Turk
Journal:  Oncotarget       Date:  2011-09

6.  TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.

Authors:  F Journe; H Id Boufker; L Van Kempen; M-D Galibert; M Wiedig; F Salès; A Theunis; D Nonclercq; A Frau; G Laurent; A Awada; G Ghanem
Journal:  Br J Cancer       Date:  2011-11-01       Impact factor: 7.640

7.  Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.

Authors:  Rolando Pérez-Lorenzo; Stephanie O Erjavec; Angela M Christiano; Raphael Clynes
Journal:  Oncotarget       Date:  2021-01-19

8.  Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients.

Authors:  P El Hajj; F Journe; M Wiedig; I Laios; F Salès; M-D Galibert; L C Van Kempen; A Spatz; B Badran; D Larsimont; A Awada; G Ghanem
Journal:  Br J Cancer       Date:  2013-03-21       Impact factor: 7.640

9.  Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma.

Authors:  Cindy L Zuleger; Chulhi Kang; Erik A Ranheim; Ilene D Kurzman; Michael D Macklin; Michael A Newton; Jedd D Wolchok; David M Vail; Elof Eriksson; Mark R Albertini
Journal:  Vet Med Sci       Date:  2017-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.